

## NOTICE TO THE BAR

### MULTICOUNTY LITIGATION APPLICATION – NEW JERSEY STATE COURT LITIGATION INVOLVING TASIGNA

The Supreme Court has received an application pursuant to Directive #02-19, “Multicounty Litigation Guidelines and Criteria for Designation (Revised),” for Multicounty Litigation (MCL) designation of New Jersey state-court litigation against Novartis Pharmaceuticals Corporation alleging injuries as a result of the use of the drug Tassigna for treatment of chronic myeloid leukemia.

The MCL application was submitted by counsel for plaintiffs. The application requests that if the designation is approved, the MCL be assigned to the Bergen Vicinage.

Anyone wishing to comment on or object to this application should provide such comments or objections in writing, with relevant supporting documentation, by **March 9, 2021** to:

Hon. Glenn A. Grant  
Acting Administrative Director of the Courts  
Attention: MCL Application – Tassigna Litigation  
Hughes Justice Complex, P.O. Box 037  
Trenton, New Jersey 08625-0037

Comments/objections may also be submitted by email to [Comments.mailbox@njcourts.gov](mailto:Comments.mailbox@njcourts.gov).

A copy of the application submitted to the Court is posted with this Notice on the Judiciary’s Internet Website at ([www.njcourts.gov](http://www.njcourts.gov)) in the Multicounty Litigation Information Center <http://www.njcourts.gov/attorneys/mcl/index.html>.

A handwritten signature in black ink, reading "Glenn A. Grant", is positioned above a horizontal line.

Glenn A. Grant, J.A.D.  
Acting Administrative Director of the Courts

Dated: February 9, 2021